Expertise in

conditions

Dr. Robert Behrens

Oncology

Mission Cancer And Blood PLLC

1221 Pleasant St Ste 100,

Des Moines, IA

Clinical Trials:Currently Recruiting for 12 Trials

Expertise in

conditions

Mission Cancer And Blood PLLC

1221 Pleasant St Ste 100,

Des Moines, IA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Behrens is an Oncologist in Des Moines, Iowa. Dr. Behrens is highly rated in 98 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Lung Cancer, Febrile Neutropenia, Bone Marrow Aspiration, and Colonoscopy.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 166 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in IA

Hospital Affiliations

St Anthony Regional Hospital & Nursing Home

University Of Iowa Hospital & Clinics

Unitypoint Health - Des Moines Iowa Methodist Medi

Crawford County Memorial Hospital

Mercyone Des Moines Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

HealthPartners

Humana

HMO
INDEMNITY
POS
PPO

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

Oscar

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

Wellmark

View 12 Less Insurance Carriers -

Locations

Mission Cancer and Blood PLLC
1221 Pleasant St Ste 100, Des Moines, IA 50309

Call: 515-282-2921

Other Locations

St. Anthony Regional Hospital
311 S Clark St, Carroll, IA 51401

Call: 712-792-3581

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

166 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Phase: Phase 2

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Cancer Moonshot Biobank Research Protocol

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Other

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bevacizumab, Osimertinib

Study Phase: Phase 3

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Carboplatin, Cisplatin, Pembrolizumab

Study Phase: Phase 2

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Drug, Other

Study Drugs: Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel

Study Phase: Phase 3

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Other

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Drug, Biological, Other

Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim

Study Phase: Phase 2

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Atezolizumab, Talazoparib

Study Phase: Phase 2

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Oral Azacitidine, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug

Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant

Study Phase: Phase 3

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure, Radiation, Other

Study Drug: Olaparib

Study Phase: Phase 2

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drug: Enzalutamide

Study Phase: Phase 2

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Other

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Completed

Publish Date: February 10, 2026

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Enrollment Status: Completed

Publish Date: February 06, 2026

Intervention Type: Other, Biological, Radiation

Study Drugs: Cetuximab, Durvalumab

Study Phase: Phase 2/Phase 3

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Enrollment Status: Suspended

Publish Date: February 05, 2026

Intervention Type: Biological, Drug, Procedure, Other

Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab

Study Phase: Phase 3

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Drug

Study Drugs: Avelumab, Cetuximab

Study Phase: Phase 2

Genomically-Guided Treatment Trial in Brain Metastases

Enrollment Status: Suspended

Publish Date: February 04, 2026

Intervention Type: Drug

Study Drugs: Abemaciclib, Paxalisib, Entrectinib

Study Phase: Phase 2

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study

Enrollment Status: Completed

Publish Date: February 04, 2026

Intervention Type: Procedure

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Completed

Publish Date: February 03, 2026

Intervention Type: Other

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2026

Intervention Type: Other, Radiation

Study Phase: Phase 3

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2026

Intervention Type: Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin

Study Phase: Phase 3

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Enrollment Status: Completed

Publish Date: January 28, 2026

Intervention Type: Radiation, Drug

Study Drug: Sorafenib Tosylate

Study Phase: Phase 3

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

View 38 Less Clinical Trials

18 Total Publications

Observational survey of financial difficulties among patients with multiple myeloma and chronic lymphocytic leukaemia treated at US community oncology clinics (Alliance A231602CD).

Journal: BMJ open

Published: June 03, 2025

View All 18 Publications

Similar Doctors

Expertise in

conditions

Dr. Daniel Buroker

Oncology

Expertise in

conditions

Dr. Daniel Buroker

Oncology

Mission Cancer And Blood PLLC

1221 Pleasant St Ste 100,

Des Moines, IA

(71.2 miles away)

515-282-2921

Languages Spoken:

English

See accepted insurances

Daniel Buroker is an Oncologist in Des Moines, Iowa. Dr. Buroker is highly rated in 79 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy.

Expertise in

conditions

Dr. Brian P. Freeman

Oncology | Hematology | Hematology Oncology

Expertise in

conditions

Dr. Brian P. Freeman

Oncology | Hematology | Hematology Oncology

State University Of Iowa

411 Laurel St, Suite A300,

Des Moines, IA

(71.4 miles away)

515-558-6576

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Brian Freeman is an Oncologist and a Hematologist in Des Moines, Iowa. Dr. Freeman is highly rated in 81 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Gamma Knife Radiosurgery. Dr. Freeman is currently accepting new patients.

Expertise in

conditions

Dr. Richard Deming

Oncology

Expertise in

conditions

Dr. Richard Deming

Oncology

MercyOne Richard Deming Cancer Center

411 Laurel Street, Suite 3300,

Des Moines, IA

(71.5 miles away)

515-643-8206

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Richard Deming is an Oncologist in Des Moines, Iowa. Dr. Deming is highly rated in 39 conditions, according to our data. His top areas of expertise are Lung Cancer, Colorectal Cancer, Astrocytoma, Gamma Knife Radiosurgery, and Tissue Biopsy.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Behrens's expertise for a condition

ConditionClose